| 前收市價 | 2.2000 |
| 開市 | 2.2000 |
| 買盤 | 0.0000 |
| 賣出價 | 2.5000 |
| 拍板 | 2.50 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 2.2000 - 2.2000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 3 |
ZacksFibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 38.46% and 53.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
InvestorPlace7 Penny Biotech Stocks to Triple Your Investment
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points. Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many upstart biotech firm
Insider MonkeyFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript May 6, 2024 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.33272 EPS, expectations were $-0.31. FGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
